<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1111/ijd.17231</dc:identifier><dc:language>eng</dc:language><dc:creator>García-González, Sergio</dc:creator><dc:creator>Villagrasa-Boli, Pablo</dc:creator><dc:creator>Bularca, Elena</dc:creator><dc:creator>Moratiel Pellitero, Alba</dc:creator><dc:creator>Prieto-Torres, Lucía</dc:creator><dc:title>Tralokinumab-related facial redness: a therapeutic challenge</dc:title><dc:identifier>ART-2024-139007</dc:identifier><dc:description>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczematous lesions, and lichenification. Treating patients with severe forms of AD is generally challenging for dermatologists. Here, we describe a case of tralokinumab-related facial redness in a patient who had a good response to the drug previously.</dc:description><dc:date>2024</dc:date><dc:source>http://zaguan.unizar.es/record/136011</dc:source><dc:doi>10.1111/ijd.17231</dc:doi><dc:identifier>http://zaguan.unizar.es/record/136011</dc:identifier><dc:identifier>oai:zaguan.unizar.es:136011</dc:identifier><dc:identifier.citation>INTERNATIONAL JOURNAL OF DERMATOLOGY 63, 11 (2024), 1605-1606</dc:identifier.citation><dc:rights>All rights reserved</dc:rights><dc:rights>http://www.europeana.eu/rights/rr-f/</dc:rights><dc:rights>info:eu-repo/semantics/closedAccess</dc:rights></dc:dc>

</collection>